Full-Time

Director GPV Compliance & Business Management

Quality Assurance

Updated on 8/25/2026

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$186.5k - $278.9k/yr

+ Incentive opportunity

Princeton, NJ, USA

Hybrid

Remote work is available, with travel as applicable.

Bachelor's

Category
QA & Testing (1)
Required Skills
Word/Pages/Docs
Quality Assurance (QA)
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • Experience working in a global setting is required.
  • Experience managing vendor relationships and vendor oversight is required.
  • At least 6 years of pharmacovigilance compliance or quality management experience in the pharmaceutical industry, or relevant leadership experience, is required.
  • Microsoft proficiency is essential.
  • Experience with Good Pharmacovigilance Practices, Good Clinical Practice, and inspections conducted by the FDA, MHRA, and other agencies is required.
  • Experience with quality compliance management systems is required.
  • Knowledge of International Council for Harmonisation, United States, and European Union pharmacovigilance regulations and requirements is required.
  • A solid background and experience in pharmaceutical quality system management under GxP is required.
  • Experience coordinating or participating in pharmacovigilance audits in the pharmaceutical industry is required.
  • Strong project management, interpersonal, communication, and presentation skills are required.
  • The ability to accomplish objectives through influence in a matrix organization is required.
  • Strong computer skills with Microsoft Word, Excel, PowerPoint, and Outlook are required.
Responsibilities
  • Lead the execution of the strategic direction of internal global pharmacovigilance compliance systems to ensure alignment with global regulatory guidelines and standards.
  • Lead a team of internal colleagues and manage a vendor team to deliver and maintain compliance frameworks across the global pharmacovigilance organization.
  • Define and implement the compliance strategy for global pharmacovigilance functional areas in collaboration with Global Quality Management and internal stakeholders.
  • Partner globally with affiliates, other Otsuka companies, external pharmaceutical organizations, Regulatory Affairs, Clinical Management, and other internal teams to ensure consistent compliance practices.
  • Coordinate activities across Compliance and Business Management sub-functions and maintain a unified approach to compliance.
  • Provide leadership and oversight of the external vendor supporting global pharmacovigilance compliance activities, including performance, quality, and regulatory alignment.
  • Lead complex projects or programs of strategic importance involving cross-functional teams.
  • Implement strategic goals established by executive leaders with direct impact on department or functional-area results.
  • Provide strategic leadership and oversight of global pharmacovigilance audit and inspection preparedness across all regions.
  • Direct the global strategy, governance, and execution of GxP regulatory inspections affecting pharmacovigilance and drive resolution through closure.
  • Oversee planning, resourcing, and strategic coordination of Global Quality audits affecting affiliates, global pharmacovigilance processes, and alliance company activities.
  • Lead governance of alliance company and global service provider pharmacovigilance audit activities.
  • Serve as a senior liaison with inspectorates, regulatory agencies, industry associations, and inter-company networks.
  • Provide strategic direction and escalation support to Local Safety Managers for pharmacovigilance audit and inspection activities.
  • Drive readiness, strategic planning, and post-inspection remediation for global pharmacovigilance audits and inspections, including oversight of corrective and preventive action development and implementation.
  • Oversee the audit and inspection governance framework for key collaborating companies.
  • Provide strategic oversight for departmental training programs that strengthen inspection readiness and pharmacovigilance quality culture.
  • Lead enterprise-wide initiatives to optimize pharmacovigilance processes for reliability, effectiveness, and operational efficiency.
  • Oversee root cause analyses and investigations into non-adherence to pharmacovigilance requirements.
  • Provide strategic leadership and oversight across global pharmacovigilance functions for the development, prioritization, and governance of pharmacovigilance-related corrective and preventive actions.
  • Guide corrective and preventive action owners through complex investigations, root-cause analysis, impact assessment, and corrective and preventive action closure.
  • Partner with Global Quality on audit and inspection responses while driving accountability among pharmacovigilance subject-matter experts.
  • Oversee closure of pharmacovigilance corrective and preventive actions and audit findings, ensuring remediation, risk mitigation, and sustainable quality improvements.
  • Provide executive oversight of corrective and preventive action development, management, and metrics tracking.
  • Review and approve pharmacovigilance corrective and preventive action records at key lifecycle stages.
  • Oversee governance and coordination of pharmacovigilance deviations, Temporary Change Controls, and standalone corrective and preventive actions.
  • Lead governance meetings with Global Quality, establish best practices, manage escalations, and support an inspection-ready pharmacovigilance quality culture.
  • Perform cross-pillar activities aligned with Contract Compliance Management, Due Diligence and Alliance Management, and Compliance Assurance.
  • Provide strategic direction, oversight, and subject-matter expertise for activities in other compliance pillars.
  • Attend global and regional meetings as required.
  • Present compliance metrics at global meetings.
  • Contribute to maintenance of the Pharmacovigilance System Master File as required.
  • Lead or assist with special projects or process development as assigned.
  • Collaborate with regional pharmacovigilance offices on process improvement initiatives and corrective and preventive actions.
  • Perform other duties as needed.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.